RESUMEN
OBJECTIVE:To ensure clinical medication safety and avoid medication errors. METHODS: Various errors occurred during 2006～2007 in the pharmacy intravenous admixture service of our hospital were analyzed in accordance with drug package inserts, Chinese Pharmacopeia, and Clinical Medication Information, meanwhile the countermeasures were formulated. RESULTS: The ratio of errors in the pharmacy intravenous admixture service was 0.001%, and the internal ratio of errors was 0.04%. The errors occurred mainly in the following steps: medical orders (by doctors), input of medical orders (by nurses), arrangement of drugs (by pharmacists), allocation of nurses, as well as the check of finished products. CONCLUSIONS: By taking the following measures such as constructing consummate quality safety management system, enhancing pharmacists’ prescription-checking ability, strengthening management on personnel, intensifying checking system etc, the incidence of errors in pharmacy intravenous admixture service can be reduced and the rational clinical medication can be promoted.
RESUMEN
OBJECTIVE:To compare the efficacy and safety between caspofungin and fluconazole in the treatment of severe pulmonary fungal infection in intensive care unit. METHODS:36 patients with systemic fungal infections in intensive care unit were randomly assigned to receive caspofungin 50 mg?d-1 which was added into 250 mL normal saline and infused in no less than 1h for 14 days after initial dose of 70 mg(caspofungin group,n=18) or fluconazole 400 mg?d-1 for 14 days by iv gtt (fluconazole group,n=18). The curative efficacy and adverse events in the two groups were observed. RESULTS:The effective rate was 100.0% in caspofungin group versus 66.7% in fluconazole group. The incidence rates were 22.2% and 72.2%,respectively. There were significant differences in the overall effective rate between two groups(P
RESUMEN
OBJECTIVE:To compare the efficacy and safety of linezolid vs.vancomycin in the treatment of MRSA-inducing ventilator-associated pneumonia in ICU.METHODS:In randomized controlled trials,54 patients with MRSA-inducing ventilator-associated pneumonia in ICU were randomly divided into 2 groups.Linezolid group (n=24) were administered with linezolid 600 mg every 12 h for 10 days,ivgtt.Vancomycin group (n=30) were given vancomycin 500 mg every 8h for 10 days ivgtt.Adverse events and the efficacy of two groups were investigated.RESULTS:Comparison results of linezolid group vs.vancomycin group were as follows:effective rates:100% vs.66.7%,MRSA eradication rates:87.5% vs.43.3%,adverse reactions rates:12.5% vs.13.3%.There were significant differences in the effective rates and MRSA eradication rates between two groups.CONCLUSION:The efficacy and safety of linezolid in the treatment of MRSA-inducing ventilator-associated pneumonia is superior to vancomycin.